Kezar Shifts Focus From Tumor Drug to Autoimmune Therapy
Kezar halts tumor drug trials, pivots to autoimmune hepatitis focus with promising zetomipzomib.
- Latest
- Trending
Kezar halts tumor drug trials, pivots to autoimmune hepatitis focus with promising zetomipzomib.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.